#VisualAbstract: Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis
1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission ...
Tag: inflammatory bowel disease
Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes
1. Patients who continued anti-tumor necrosis factor (TNF) after 24 weeks of pregnancy had improved inflammatory bowel disease (IBD) activity ...
ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity
1. Patients with the ACKR1 variant (CC genotype) had an elevated risk of azathioprine discontinuation attributed to hematopoietic toxicity. 2. ...
Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis
1. Upadacitinib led to significantly greater percentages of clinical remission compared to placebo for both induction and maintenance studies. 2. ...
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE ...
Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the ...